-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Inhibitor Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from 2012 to Q3 2025.
- Inhibitor Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2025 was 173M shares, a 0.15% increase year-over-year.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 172M shares, a 0.18% increase from 2023.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 172M shares, a 53% decline from 2022.
- Inhibitor Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 366M shares, a 2.68% decline from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)